ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.

IOVA Iovance Biotherapeutics Inc

8.0998
-0.0602 (-0.74%)
17 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Iovance Biotherapeutics Inc IOVA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
-0.0602 -0.74% 8.0998 17:30:22
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
8.05 7.87 8.165 8.08 8.16
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/6/202417:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/6/202417:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202416:15EDGAR2Form 8-K - Current report
05/6/202419:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202419:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/6/202419:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202407:01EDGAR2Form 8-K - Current report
24/5/202415:01GLOBEIovance Biotherapeutics to Present at Upcoming Conferences..
23/5/202416:00GLOBEIovance Biotherapeutics Announces Clinical Data in Frontline..
17/5/202416:15EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
17/5/202416:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
09/5/202416:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202415:06EDGAR2Form 8-K - Current report
09/5/202415:01GLOBEIovance Biotherapeutics Reports First Quarter 2024 Financial..
01/5/202405:01GLOBEIovance Biotherapeutics to Host First Quarter 2024 Financial..
30/4/202405:01GLOBEIovance Biotherapeutics to Present at Upcoming Conferences
24/4/202415:01GLOBEIovance Biotherapeutics to Present Clinical and..
19/4/202416:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
22/3/202416:30GLOBEIovance Biotherapeutics Reports Inducement Grants under..
06/3/202417:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:56EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202416:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/3/202407:00EDGAR2Form 8-K - Current report
04/3/202405:30GLOBEIovance Biotherapeutics Announces FDA has Lifted Clinical..
01/3/202416:00GLOBEIovance Biotherapeutics to Present at Upcoming Conferences
29/2/202406:30EDGAR2Form 8-K - Current report
28/2/202415:05EDGAR2Form 8-K - Current report
28/2/202415:01GLOBEIovance Biotherapeutics Reports Fourth Quarter and Full Year..
22/2/202415:53EDGAR2Form 8-K - Current report
22/2/202407:45GLOBEIovance Biotherapeutics to Host Fourth Quarter and Full-Year..
21/2/202415:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
20/2/202416:23EDGAR2Form 8-K - Current report
20/2/202415:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/2/202405:30GLOBEIovance Biotherapeutics, Inc. Announces Pricing of $211..
20/2/202405:03EDGAR2Form 8-K - Current report
16/2/202416:30GLOBEIovance Biotherapeutics Reports Inducement Grants under..
16/2/202414:38GLOBEIovance Biotherapeutics to Host Conference Call and Webcast..
16/2/202414:19GLOBEIovance’s AMTAGVI™ (lifileucel) Receives U.S. FDA..
14/2/202405:16EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
19/1/202416:15GLOBEIovance Biotherapeutics Reports Inducement Grants under..
18/1/202417:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202417:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/1/202417:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202416:03EDGAR2Form 8-K - Current report
28/12/202306:27IHMARKETNEWSWall Street Highlights: Amazon to Introduce Ads on Prime..
27/12/202316:00EDGAR2Form 8-K - Current report

Su Consulta Reciente

Delayed Upgrade Clock